About Marina Biotech (OTCMKTS:MRNA)
Marina Biotech, Inc., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company has three clinical development programs, such as IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication of familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. Its preclinical pipeline includes oligotherapeutics for the treatment of bladder cancer, inflammatory bowel, and duchenne muscular dystrophy diseases. The company is based in City of Industry, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales15.47
Price / CashN/A
Book Value$0.04 per share
Price / Book25.00
EPS (Most Recent Fiscal Year)N/A
Return on Equity-312.76%
Return on Assets-98.82%
Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions
What is Marina Biotech's stock symbol?
Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."
How were Marina Biotech's earnings last quarter?
Marina Biotech, Inc. (OTCMKTS:MRNA) issued its quarterly earnings results on Monday, November, 21st. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.05 million for the quarter. View Marina Biotech's Earnings History.
When is Marina Biotech's next earnings date?
Who are some of Marina Biotech's key competitors?
Some companies that are related to Marina Biotech include IntelGenx Technologies (IGXT), Vivus (VVUS), Celsion (CLSN), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), PLx Pharma (PLXP), Chiasma (CHMA), Edge Therapeutics (EDGE), Lipocine (LPCN), Nemus Bioscience (NMUS), Egalet (EGLT), Benitec Biopharma (BNTC), ProPhase Labs (PRPH), OvaScience (OVAS) and TapImmune (TPIV).
Who are Marina Biotech's key executives?
Marina Biotech's management team includes the folowing people:
- Dr. Vuong Trieu, Exec. Chairman (Age 55)
- Mr. Joseph W. Ramelli, CEO & Interim Pres (Age 50)
- Mr. Amit Shah, Chief Financial Officer
- Mr. Mihir Munsif, Chief Operating Officer (Age 55)
- Dr. Michael V. Templin Ph.D., DABT, Chief Technology Officer
Has Marina Biotech been receiving favorable news coverage?
Media headlines about MRNA stock have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Marina Biotech earned a media sentiment score of 0.18 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.68 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Marina Biotech?
Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Marina Biotech's stock price today?
One share of MRNA stock can currently be purchased for approximately $1.00.
How big of a company is Marina Biotech?
Marina Biotech has a market capitalization of $10.63 million and generates $680,000.00 in revenue each year. Marina Biotech employs 7 workers across the globe.
How can I contact Marina Biotech?
Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]
MarketBeat Community Rating for Marina Biotech (MRNA)MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Marina Biotech (OTCMKTS:MRNA) Analyst Ratings History
(Data available from 4/24/2016 forward)
Marina Biotech (OTCMKTS:MRNA) Earnings History and Estimates Chart
Marina Biotech (OTCMKTS MRNA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/21/2018|| || || || || || || || |
|11/21/2016||Q3 2016||($0.05)||$0.05 million||View||N/A|
|3/31/2016||Q4 2015||($0.20)||$0.20 million||View||N/A|
|11/16/2015||Q3 2015||($0.60)||$0.08 million||View||N/A|
|8/13/2015||Q2 2015||$0.30||$0.40 million||View||N/A|
|2/25/2015||Q4 2014||$4.90||$0.50 million||View||N/A|
Marina Biotech (OTCMKTS:MRNA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Marina Biotech (OTCMKTS MRNA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 50.00%
Marina Biotech (OTCMKTS MRNA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/9/2017||Vuong Trieu||Chairman||Buy||10,000||$0.39||$3,900.00||11,127,141|| |
|6/7/2017||Vuong Trieu||Chairman||Buy||22,500||$0.39||$8,775.00||11,117,141|| |
|4/6/2017||Joseph W Ramelli||CEO||Buy||35,500||$0.39||$13,845.00||440,653|| |
|4/5/2017||Joseph W Ramelli||CEO||Buy||97,550||$0.31||$30,240.50||405,153|| |
|2/6/2017||Vuong Trieu||Chairman||Buy||862,068||$0.29||$249,999.72||11,094,641|| |
|4/16/2014||Joseph W Ramelli||Director||Buy||26,300||$0.76||$19,988.00|| |
|2/10/2014||Cashman Llp Pryor||Major Shareholder||Sell||108,041||$0.99||$106,960.59|| |
|10/4/2013||Cashman Llp Pryor||Major Shareholder||Sell||100,000||$0.25||$25,000.00|| |
Marina Biotech (OTCMKTS MRNA) News Headlines
|Marina Biotech Announces a New Publication on Prestalia®|
finance.yahoo.com - February 27 at 4:37 PM
|Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio|
finance.yahoo.com - January 16 at 9:34 AM
|Marina Biotech (MRNA) Lowered to Sell at ValuEngine|
www.americanbankingnews.com - December 3 at 6:30 AM
|Marina Biotech Appoints Isaac Blech to its Board of Directors|
finance.yahoo.com - November 27 at 3:45 PM
|Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives|
finance.yahoo.com - October 20 at 6:29 AM
|Marina Biotech Appoints Amit Shah as Chief Financial Officer|
finance.yahoo.com - October 5 at 8:59 AM
|Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives|
finance.yahoo.com - August 21 at 8:06 PM
|Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market|
finance.yahoo.com - August 3 at 5:57 AM
|Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform|
finance.yahoo.com - July 26 at 1:11 AM
|Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®|
finance.yahoo.com - July 25 at 4:06 AM
|Marina Biotech up 11% on SMARTICLES license deal|
seekingalpha.com - July 20 at 1:44 AM
|Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics|
finance.yahoo.com - July 20 at 1:44 AM
|Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman|
finance.yahoo.com - July 5 at 8:41 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Off|
biz.yahoo.com - February 14 at 8:15 PM
|Marina Biotech Announces a License Agreement to SMARTICLES|
us.rd.yahoo.com - February 7 at 7:58 PM
|10:28 am Marina Biotech (thinly-traded) entered into a license agreement regarding its SMARTICLES platform; could receive up to $90 mln in success based milestones|
us.rd.yahoo.com - February 7 at 7:58 PM
|MARINA BIOTECH, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements a|
biz.yahoo.com - January 28 at 1:50 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events|
biz.yahoo.com - December 14 at 7:19 PM
|MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dis|
biz.yahoo.com - November 18 at 5:51 PM
|Marina Biotech (MRNA) to Merge with IthenaPharma|
www.streetinsider.com - November 16 at 9:56 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - August 1 at 9:17 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Other Events|
biz.yahoo.com - June 24 at 9:17 AM
|MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - June 2 at 9:58 AM
Marina Biotech (OTCMKTS:MRNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Marina Biotech (OTCMKTS:MRNA) Income Statement, Balance Sheet and Cash Flow Statement
Marina Biotech (OTCMKTS MRNA) Stock Chart for Tuesday, April, 24, 2018